In Talc Litigation On ‘Baseless Scientific Claims,’ J&J Says Settlement Offers Plaintiffs 'Certainty’
First-Quarter Results Including 7.4% Consumer Health Sales Growth Prompt Guidance Boost
Firm reiterates stance on safety of talc as it reports 7.4% Q1 growth in consumer health product sales contributes to earnings guidance boost. It reports $3.85bn consumer health sales with US sales up 11.4% to $1.74bn and international sales 4.4% to $2.12bn.
You may also be interested in...
During Kenvue’s first earnings briefing, CEO Thibaut Mongon touts adding products and extending lines but repeatedly references attention to fundamentals of manufacturing and marketing OTC drugs, personal and skin care lines and other consumer health products.
Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.
“That’s what makes this space very attractive, the ability to expand usage occasions to give consumers around the world new opportunities to take care of their health,” says CEO Thibaut Mongon. Some investors aren’t clear on what to expect from company operating entirely in consumer health since spinout from J&J.